Overview

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with nonmetastatic rhabdomyosarcoma.
Phase:
Phase 3
Details
Lead Sponsor:
European Paediatric Soft Tissue Sarcoma Study Group
Collaborators:
Children's Cancer and Leukaemia Group
Dutch Childhood Oncology Group
Italian Association for Pediatric Hematology Oncology
Treatments:
Carboplatin
Cyclophosphamide
Dactinomycin
Doxorubicin
Etoposide
Ifosfamide
Liposomal doxorubicin
Topotecan
Vincristine
Vinorelbine